Logo
x

Search category

Subscribe Now

Bristol Myers Squibb

BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint

BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint

  • December 8, 2023
BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan

BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan

  • December 7, 2023
Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation o...

  • May 17, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs

CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs

  • March 21, 2023
BMS Reports P-III (COMMANDS) Study Results of Reblozyl (luspatercept-aamt) for Myelodysplastic Syndromes

BMS Reports P-III (COMMANDS) Study Results of Reblozyl (luspatercept-aamt) for Myelodysplastic Syndromes

  • October 31, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.